hydralazine has been researched along with lisinopril in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (17.65) | 18.7374 |
| 1990's | 7 (41.18) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brunner, HR; Hayoz, D; Meister, JJ; Perret, F; Tardy, Y; Waeber, B | 1 |
| Ganten, D; Hellmann, T; Keuneke, C; Metzger, R; Peters, J; Yacullo, R | 1 |
| Drummer, OH; Froomes, P; McLean, AJ; McNeil, JJ; Smith, HJ | 1 |
| Hartmann, JF; Hayes, NS; Keegan, ME; Slater, EE; Szemplinski, M | 1 |
| Fyhrquist, F; Grönhagen-Riska, C; Karlberg, BE; Ohman, KP; Tikkanen, I | 1 |
| Giles, TD | 1 |
| Corradi, L; Fogari, R; Lusardi, P; Mugellini, A; Tettamanti, F; Zoppi, A | 1 |
| Fukamizu, A; Ishikawa, K; Kai, T; Kurooka, A; Murakami, K; Shimada, S; Sugimura, K; Takenaka, T | 1 |
| Ishikawa, K; Kai, T; Kurooka, A; Shimada, S; Sugimura, K | 1 |
| Benedetti, G; Benigni, A; Bruzzi, I; Corna, D; Noris, M; Remuzzi, G; Todeschini, M; Zoja, C | 1 |
| Ishikawa, K; Kai, T | 1 |
| Hasslacher, C; Kempe, HP; Koenen, C; Lang, C; Werle, E | 1 |
| Christian, R; Colon, PJ; Cushman, WC; Einhorn, PT; Ford, CE; Goff, DC; Henriquez, MA; Margolis, KL; Piller, LB; Vidt, DG; Wong, ND; Wright, JT | 1 |
2 review(s) available for hydralazine and lisinopril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Optimizing the treatment of heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcium Channel Blockers; Captopril; Clinical Trials as Topic; Contraindications; Digitalis; Digoxin; Diuretics; Enalapril; Heart Failure; Humans; Hydralazine; Lisinopril; Nitrates; Plants, Medicinal; Plants, Toxic; Randomized Controlled Trials as Topic; Stroke Volume | 1994 |
5 trial(s) available for hydralazine and lisinopril
| Article | Year |
|---|---|
Non-invasive determination of arterial diameter and distensibility by echo-tracking techniques in hypertension.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Animals; Arteries; Atenolol; Blood Pressure; Captopril; Compliance; Dipeptides; Double-Blind Method; Humans; Hydralazine; Hypertension; Lisinopril; Nitrendipine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Ultrasonography | 1992 |
Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Drug Interactions; Drug Therapy, Combination; Enalapril; Humans; Hydralazine; Lisinopril; Male | 1989 |
Enalapril and lisinopril in renovascular hypertension--antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Dipeptides; Enalapril; Humans; Hydralazine; Hypertension, Renovascular; Lisinopril; Middle Aged; Prazosin | 1984 |
Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Catecholamines; Diuretics; Drug Therapy, Combination; Echocardiography; Heart Rate; Humans; Hydralazine; Hypertension; Hypertrophy, Left Ventricular; Lisinopril; Male; Middle Aged; Regression Analysis | 1995 |
Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Black People; Blood Pressure; Canada; Chlorthalidone; Clonidine; Double-Blind Method; Doxazosin; Female; Heart Diseases; Hispanic or Latino; Humans; Hydralazine; Hypertension; Hypolipidemic Agents; Lisinopril; Male; Middle Aged; Puerto Rico; Reserpine; Treatment Outcome; United States; United States Virgin Islands; White People | 2007 |
10 other study(ies) available for hydralazine and lisinopril
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
The role of tissue renin-angiotensin systems in hypertension and effects of chronic converting-enzyme inhibition.
Topics: Adrenal Glands; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Animals; Blood Pressure; Captopril; Enalapril; Gene Expression Regulation; Heart; Hydralazine; Hypertension; Isoquinolines; Kidney; Lisinopril; Male; Quinapril; Rats; Rats, Inbred SHR; Renin; Renin-Angiotensin System; RNA, Messenger; Tetrahydroisoquinolines | 1990 |
Effects of the angiotensin converting enzyme inhibitor, lisinopril, on normal and diabetic rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Diabetes Mellitus, Experimental; Enalapril; Hydralazine; Hypertension; Lisinopril; Rats; Renin; Renin-Angiotensin System; Streptozocin | 1988 |
Tissue-localized angiotensin II enhances cardiac and renal disorders in Tsukuba hypertensive mice.
Topics: Angiotensin II; Angiotensinogen; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Catecholamines; Humans; Hydralazine; Hypertension; Kidney Diseases; Lisinopril; Mice; Mice, Inbred C57BL; Mice, Transgenic; Renin | 1998 |
Renin-angiotensin system stimulates cardiac and renal disorders in Tsukuba hypertensive mice.
Topics: Angiotensin II; Angiotensinogen; Animals; Blood Pressure; Cardiomegaly; Humans; Hydralazine; Hypertension; Kidney Diseases; Lisinopril; Mice; Mice, Inbred C57BL; Renin; Renin-Angiotensin System; Survival Rate | 1999 |
Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Creatinine; Disease Progression; Eating; Endothelin-1; Hydralazine; Hydrochlorothiazide; Kidney; Lisinopril; Male; Molsidomine; Nephrectomy; Nitric Oxide; Nitric Oxide Donors; Nitrous Oxide; Rats; Rats, Sprague-Dawley; Reserpine | 1999 |
Lisinopril reduces left ventricular hypertrophy and cardiac polyamine concentrations without a reduction in left ventricular wall stress in transgenic Tsukuba hypertensive mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Hydralazine; Hypertension; Hypertrophy, Left Ventricular; Lisinopril; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myocardium; Organ Size; Osmolar Concentration; Polyamines; Reference Values; Stress, Mechanical; Systole; Ventricular Function, Left | 2000 |
The influence of the ACE inhibitor lisinopril on the glomerular metabolism of proteolytic enzymes in diabetic rats.
Topics: Acetylglucosaminidase; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Diabetes Mellitus, Experimental; Endopeptidases; Glycated Hemoglobin; Hydralazine; Kidney Glomerulus; Lisinopril; Male; Rats; Rats, Wistar; Reference Values | 2000 |